Part:BBa_K779305
rtTA3 MammoBlock
Testing rtTA3:https://parts.igem.org/Main_Page
The circuit that MIT iGEM 2012 tested:
In this circuit, a constitutive mammalian promoter, Hef1A, drives expression of a trans-activator, rtTA3. rtTA3 activates the Tre-Tight promoter in the prescence of doxycycline (DOX), a small molecule. Tre-Tight drives expression of mKate, a red fluorescent protein. In addition, a plasmid containing the Hef1A promoter driving expression of TagBFP, a blue fluorescent protein, is used as a transfection marker.
Experimental Data:
In this system, we have constitutive expression of rtTA3 driven by the Hef1A promoter. In the presence of doxycycline (DOX), rtTA3 can activate the Tre-Tight (TreT) promoter, which is driving expression of mKate, a red fluorescent protein.
100,000 HEK293 cells were transfected with equimolar rations of Hef1a:rTTA3, TreT:mKate, and Hef1a:TagBFP (as a transfection marker), standardized to 500 ng total plasmid DNA, with 1.65 uL Lipofectamine 2000. After 48 hours, cells were imaged on a Leica Confocal Microscope at 10x. We can see that we have transfection, since cells are fluorescing blue. Also, we can see that as we increase the concentration of DOX present, we see an increase in red fluorescence.
100,000 HEK293 cells were transfected with equimolar rations of Hef1a:rTTA3, TreT:mKate, and Hef1a:TagBFP (as a transfection marker), standardized to 500 ng total plasmid DNA, with 1.65 uL Lipofectamine 2000. After 24 hours, DOX was then added to 16 different concentrations ranging from 0.1 nM to 5000 nM. Lastly, cells were harvested for flow cytometry after 48 hrs and allowed to count 10,000 events. As we increase concentrations of DOX, the mean red fluorescence increases.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
| n/a | rtTA3 MammoBlock |